A Phase 1, Single-Dose, Open-Label, Randomized Cross-Over Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
Status: Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2019
Price : $35 *
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Pharmacokinetics
- Sponsors AbbVie
- 14 Jun 2019 Planned End Date changed from 24 May 2022 to 7 Jun 2024.
- 14 Jun 2019 Planned primary completion date changed from 13 Mar 2021 to 7 Jun 2024.
- 14 Jun 2019 Planned initiation date changed from 10 May 2020 to 24 May 2022.